A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 4-Week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-Daily in Subjects With COPD.

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 4-Week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-Daily in Subjects With COPD.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs Darotropium bromide (Primary) ; Vilanterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Mar 2009 Actual patient number (61) added as reported by ClinicalTrials.gov.
    • 25 Mar 2009 Actual patient number (61) added as reported by ClinicalTrials.gov.
    • 25 Mar 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top